Stoke Therapeutics (NASDAQ:STOK) issued its quarterly earnings results on Wednesday. The company reported ($1.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.58), Bloomberg Earnings reports.
Shares of NASDAQ:STOK traded up $0.40 during midday trading on Thursday, reaching $30.67. The company had a trading volume of 900 shares, compared to its average volume of 90,575. The stock has a 50 day simple moving average of $26.46. Stoke Therapeutics has a 52-week low of $22.01 and a 52-week high of $31.76.
A number of equities analysts recently weighed in on STOK shares. JPMorgan Chase & Co. started coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They issued an “overweight” rating and a $34.00 price target on the stock. Canaccord Genuity started coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They issued a “buy” rating and a $44.00 price target on the stock. Credit Suisse Group started coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They issued an “outperform” rating and a $35.00 price target on the stock. Finally, Cowen reissued a “buy” rating on shares of Stoke Therapeutics in a report on Thursday.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.